Aspen Pharmacare traded at 14,991.00 this Tuesday July 14th, decreasing 233.00 or 1.53 percent since the previous trading session. Looking back, over the last four weeks, Aspen Pharmacare lost 3.39 percent. Over the last 12 months, its price rose by 33.18 percent. Looking ahead, we forecast Aspen Pharmacare to be priced at 14,632.21 by the end of this quarter and at 13,300.81 in one year, according to Trading Economics global macro models projections and analysts expectations.
Aspen Pharmacare Holdings Limited is a South Africa-based global specialty and branded pharmaceutical company with a commercial footprint covering more than 50 countries and complex manufacturing capabilities in both active pharmaceutical ingredients (APIs) and finished dose form. The Company is focused on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through its key business segments: Manufacturing and Commercial Pharmaceuticals. The Manufacturing segment relates to the manufacture and sale of APIs and finished dose form products to third-party customers. Its Commercial Pharmaceuticals segment comprises Regional Brands and Sterile Focus Brands that include Anaesthetics and Thrombosis products. It operates approximately 23 manufacturing facilities on six continents. Its manufacturing capabilities cover a wide variety of product-types, including orals, liquids, steriles, biologicals and APIs.